Rapid Readouts: The Phase 1/2 ANCHOR Trial for Melphalan Flufenamide in Relapsed/Refractory Multiple Myeloma

Related Videos
Amandeep Godara, MBBS
Expert on AML
Expert on AML
Matthew Brunner, MD, assistant professor, hematologic specialist, medical oncology, and palliative care, Department of Medicine, University of Wisconsin Carbone Cancer Center
Matthew Brunner, MD, assistant professor, hematologic specialist, medical oncology, and palliative care, Department of Medicine, University of Wisconsin Carbone Cancer Center
Adam D. Cohen, MD, director, Myeloma Immunotherapy, associate professor in medicine, hematology/oncology, Abramson Cancer Center, University of Pennsylvania
Craig Sauter, MD
Paul G. Richardson, MD
Experts on AML
Expert on AML
Related Content

FDA Grants Orphan Drug Designation to ISB 1442 for Relapsed/Refractory Multiple Myeloma

March 21st 2023

Jakubowiak Highlights PFS Benefit Seen With KRd Maintenance in Newly Diagnosed Multiple Myeloma

March 2nd 2023

Siltuximab Resolves CRS/ICANS After CAR T-cell Therapy for Hematologic Malignancies

March 16th 2023

FDA Approval Insights: Zanubrutinib in CLL and SLL

February 16th 2023

FDA Approves Nelarabine Injection for T-cell Leukemia and Lymphoma

March 13th 2023

Survey Reveals Importance of Precise PV Treatment Guidelines and Research

March 13th 2023

FDA Grants Orphan Drug Designation to ISB 1442 for Relapsed/Refractory Multiple Myeloma

March 21st 2023

Jakubowiak Highlights PFS Benefit Seen With KRd Maintenance in Newly Diagnosed Multiple Myeloma

March 2nd 2023

Siltuximab Resolves CRS/ICANS After CAR T-cell Therapy for Hematologic Malignancies

March 16th 2023

FDA Approval Insights: Zanubrutinib in CLL and SLL

February 16th 2023

FDA Approves Nelarabine Injection for T-cell Leukemia and Lymphoma

March 13th 2023

Survey Reveals Importance of Precise PV Treatment Guidelines and Research

March 13th 2023

FDA Grants Orphan Drug Designation to ISB 1442 for Relapsed/Refractory Multiple Myeloma

March 21st 2023

Jakubowiak Highlights PFS Benefit Seen With KRd Maintenance in Newly Diagnosed Multiple Myeloma

March 2nd 2023

Siltuximab Resolves CRS/ICANS After CAR T-cell Therapy for Hematologic Malignancies

March 16th 2023

FDA Approval Insights: Zanubrutinib in CLL and SLL

February 16th 2023

FDA Approves Nelarabine Injection for T-cell Leukemia and Lymphoma

March 13th 2023

Survey Reveals Importance of Precise PV Treatment Guidelines and Research

March 13th 2023